Aidoc raises $150M to advance clinical AI foundation model
The company wants AI to support all complex diagnostic decisions by 2030 to prevent diagnostic errors and delays.
Aidoc raises $150M to advance clinical AI foundation model Read More »
Uncategorized
Novartis unveils North Carolina API plant as final piece of $23B US expansion
The new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities across three sites.
Novartis unveils North Carolina API plant as final piece of $23B US expansion Read More »
AstraZeneca’s breast cancer drug fails to earn backing of FDA advisory committee
Members of the FDA’s Oncologic Drugs Advisory Committee questioned the design of AstraZeneca’s Phase 3 trial of camizestrant, which involved switching treatments at the point of mutation detection, as opposed to the current practice of changing regimens upon disease progression.
AstraZeneca’s breast cancer drug fails to earn backing of FDA advisory committee Read More »
Axsome wins first non-antipsychotic FDA approval for Alzheimer’s agitation
Alzheimer’s disease agitation could mean peak sales of over $2.1 billion for Axsome’s Auvelity, according to analysts at William Blair.
Axsome wins first non-antipsychotic FDA approval for Alzheimer’s agitation Read More »
Amgen positions MariTide as potential ‘best monthly’ obesity drug
Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own investigational obesity asset MariTide, which could open up monthly or more infrequent dosing schedules.
Amgen positions MariTide as potential ‘best monthly’ obesity drug Read More »
FDA taps Szarama as acting CBER director as Prasad’s tumultuous tenure ends
Katherine Szarama, who has served as Prasad’s deputy at the Center for Biologics Evaluation and Research since December, joins a long list of temporary leaders at the Department of Health and Human Services.
FDA taps Szarama as acting CBER director as Prasad’s tumultuous tenure ends Read More »
Corcept ties ALS drug to improved 2-year survival as Phase 3 start date nears
Corcept Therapeutics’ ALS drug was linked to an 87% reduction in the risk of death, a result the biotech hopes to replicate in an upcoming Phase 3 trial.
Corcept ties ALS drug to improved 2-year survival as Phase 3 start date nears Read More »
Rendimiento y confort: la ciencia detrás del calzado deportivo moderno
El calzado deportivo moderno dejó de ser solo “una zapatilla cómoda”. Hoy es un sistema: materiales que reaccionan al impacto, estructuras que guían el movimiento, tejidos que regulan temperatura y diseños que buscan una sensación especí …
Rendimiento y confort: la ciencia detrás del calzado deportivo moderno Read More »
Merck drops early-stage TROP ADC, keeps deal doors open as Keytruda clock ticks
On the heels of several big buys, Merck still has eyes for M&A—particularly in the oncology, immunology and cardiometabolic spaces—as the quest continues for a candidate that can top Keytruda.
Merck drops early-stage TROP ADC, keeps deal doors open as Keytruda clock ticks Read More »
Cigna exits ACA exchanges despite dramatic profit growth in Q1
The insurer plans to say goodbye to the ACA exchanges after this year, and is exploring a potential sale of its controversial claims review subsidiary. Both businesses were more trouble than they were worth, executives said.
Cigna exits ACA exchanges despite dramatic profit growth in Q1 Read More »